Latest Biotech News

The FDA approved Gilead’s hepatitis D therapy Hepcludex (bulevirtide) roughly four years after the agency rejected the drug earlier, citing manufacturing and distribution concerns. The approval...

Researchers at Sanford Burnham Prebys and collaborators at the University of Illinois Chicago reported in Science Advances that phosphoinositide kinases PI5P4Ks help regulate cholesterol...

A University of Pennsylvania and Children’s Hospital of Philadelphia report that an mRNA-based CRISPR base editing therapy delivered to infant “Baby KJ” with CPS1 deficiency produced meaningful...

Parabilis filed for an initial public offering on the heels of a strategic research collaboration with Regeneron. The partnership spans up to $2.3 billion in potential payments and covers...

QEt’s proposed €5 billion cross-sector growth fund is positioned to address European biotech’s funding shortfall by creating another homegrown route for growth capital. The initiative is framed...

China’s new rules for investigator-initiated trials (IITs) are expected to tighten oversight while legitimizing pathways for modalities beyond cell and gene therapies, according to reporting on...

Ahead of the 2026 ASCO Annual Meeting, organizers lifted the pre-meeting embargo on May 21 and highlighted multiple trial readouts across lung, gastrointestinal, and genitourinary cancers. The...

Vizgen laid off an unspecified number of employees as part of a strategic reorganization, according to company statements and employee reports. The spatial technology company said it is investing...

The FDA has approved datopotamab deruxtecan (Datroway; Dato-DXd) as a first-line option for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for...

Gilead won US approval for its hepatitis D drug Hepcludex (bulevirtide) after the FDA previously rejected the therapy roughly four years earlier. The agency cited manufacturing and distribution...

Ahead of ASCO 2026, abstract “snapshots” released by conference organizers are spotlighting oncology strategies that expand beyond KRAS in pancreatic cancer. Coverage also points to strong...

Parabilis filed for an initial public offering one day after signing a strategic collaboration with Regeneron that could reach up to $2.3 billion. The deal centers on “antibody-Helicon...

Biocentury coverage points to Q’s proposed €5 billion cross-sector growth fund as a potential tool to narrow Europe’s biotech capital gap. The concept is aimed at increasing the availability of...

New preclinical work indicates that targeting cholesterol transport enzymes could suppress tumor growth by starving cancer cells of needed lipid trafficking. Researchers reported that blocking...

Researchers described an interpretable machine-learning model intended for early detection of pediatric sepsis using routine lab inputs. By emphasizing explainability, the approach aims to make...

The WHO and CDC ramped up diagnostic testing for Bundibugyo Ebola as the outbreak in the DRC escalated in spread risk. WHO raised the threat level from High to Very High after assessing the...

AbbVie announced a new round of 85 layoffs tied to its Irvine, California site within its eye-care business, effective July 20. The WARN notice continues a pattern of workforce adjustments at the...

University of Pennsylvania investigators and clinicians discussed the Philadelphia “Baby KJ” CRISPR base-editing case study, characterizing it as a single-patient expanded access effort rather...

FDA has granted approval to Gilead’s hepatitis D therapy Hepcludex (bulevirtide) after the agency previously rejected the drug over manufacturing and distribution issues. The decision reopens a...

FDA approved Daiichi Sankyo and AstraZeneca’s TROP2-directed antibody-drug conjugate Datroway (datopotamab deruxtecan-dlnk) for adults with unresectable or metastatic triple-negative breast cancer...